Sagent Pharmaceuticals, which markets generic injectable drugs to the hospital market, will see its quiet period end on Monday, May 30. On April 19, the company raised $92 million by offering 5.75 million shares at $16, at high end of the range of $14 to $16. Morgan Stanley, BofA Merrill Lynch and Jefferies & Co. acted as lead managers on the deal.
